Skip to main content
Figure 7 | Arthritis Research & Therapy

Figure 7

From: Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics

Figure 7

Multiple sites of allopurinol action on pathways of purine and pyrimidine metabolism. Reactions inhibited by allopurinol are shown in red; reactions unaffected are shown in green. Allopurinol or its metabolites also result in depletion of intracellular 5-phosphoribosyl 1-pyrophosphate (PRPP) concentrations. AMP, adenosine monophosphate; CTP, cytosine triphosphate; GMP, guanosine monophosphate; HGPRT, hypoxanthine-guanine phosphoribosyltransferase; IMP, inosine monophosphate; OMPDC, orotidine-5'-monophosphate decarboxylase; OMP, orotidine monophosphate; OPRT, orotate phosphoribosyltransferase; PNP, purine nucleoside phosphorylase; PRPP, 5-phosphoribosyl 1-pyrophosphate; UMP, uridine monophosphate; UTP, uridine triphosphate; XOD, xanthine oxidase.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us